REG - CRISM Therapeutics - Notice of Interim Results & IMC Presentation

CRISM' TherapeuticsAnnouncement

09/09/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240909:nRSI2974Da&default-theme=true

RNS Number : 2974D  CRISM Therapeutics Corporation  09 September 2024

 

9 September 2024

 

 

CRISM Therapeutics Corporation

("CRISM", "CRISM Therapeutics" or the "Company")

 

Notice of Interim Results and Presentation via Investor Meet Company

 

CRISM Therapeutics Corporation (AIM: CRTX), the innovative UK drug delivery
company focused on the localised delivery of chemotherapy drugs, will announce
its Interim Results for the six months ended 30 June 2024 on Thursday, 19
September 2024.

Andrew Webb, CEO of CRISM Therapeutics, will provide a live presentation via
Investor Meet Company on 19 September 2024 at 12.00pm BST.

The presentation is open to all existing and potential shareholders. Questions
can be submitted pre-event via the Investor Meet Company dashboard up until 18
September 2024, 9.00am BST, or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet CRISM
Therapeutics via:
https://www.investormeetcompany.com/crism-therapeutics-corporation/register-investor
(https://urldefense.com/v3/__https:/www.investormeetcompany.com/crism-therapeutics-corporation/register-investor__;!!H_q-o1I4kFo!m0g5hhYxGwEivzj-oSefT-XE3-neHGcysSzlo0seYqtPGgpUC6cLqeKLHZuHw6nmh0MYjC9kjvFgcGrIwrO1UYT4JDPcuKului4IdllYqDg$)

Investors who already follow the Company on the Investor Meet Company platform
will automatically be invited.

-Ends-

 

 

Enquiries:

 

 Company                         Nomad and Broker                  Financial PR
 CRISM Therapeutics Corporation  S.P. Angel Corporate Finance LLP  Burson Buchanan
 Andrew Webb, CEO                Richard Morrison                  Mark Court / Jamie Hooper

 Chris McConville, CSO           Adam Cowl                         CRISM@buchanancomms.co.uk
 via Burson Buchanan             +44 (0) 20 3470 0470              +44 (0) 20 7466 5000

 

 

About CRISM Therapeutics Corporation

CRISM Therapeutics Corporation has developed an innovative drug delivery
technology to improve the clinical performance of cancer treatments for solid
tumours through the local delivery of chemotherapy drugs.

ChemoSeed, CRISM's lead product, can be implanted directly into the tumour or
the resection margin following the removal of a tumour. This directs that
therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour
tissue or cover the entire resection margin. In the case of treating
high-grade glioma, ChemoSeeds can be implanted during surgery thereby
bypassing the blood brain barrier, which prevents other treatments from being
able to reach the tumour and be effective.

CRISM plans to submit a clinical trial application in H2 2024 for ChemoSeed®
in high-grade glioma.  Based on preclinical data, the Tessa Jowell BRAIN
MATRIX Scientific Advisory Board has approved ChemoSeed in a phase II platform
clinical trial which is an efficient and cost-effective clinical development
opportunity.

For more information please visit: https://www.crismtherapeutics.com/
(https://www.crismtherapeutics.com/)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORQKABDQBKDACK